3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
11
Recurrence
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Burkitt Lymphoma
8
Lymphoma, Follicular
5
Lymphoma
2
Leukemia
2
Neoplasm, Residual
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Interventions
Rituximab
130
Cyclophosphamide
41
Bendamustine Hydrochloride
39
venetoclax
25
fludarabine
25
obinutuzumab
24
Lenalidomide
23
ibrutinib
22
Gemcitabine
22
Vincristine
20
Prednisone
20
tositumomab I-131
19
Doxorubicin
19
plerixafor
14
Dexamethasone
14
Granulocyte Colony-Stimulating Factor
12
pirtobrutinib
11
Brentuximab Vedotin
11
glofitamab
10
tocilizumab
9
pembrolizumab
9
ibritumomab tiuxetan
9
Etoposide
9
Azacitidine
9
polatuzumab vedotin
8
parsaclisib
8
copanlisib
8
acalabrutinib
8
Drug Therapy
8
ublituximab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Non-Hodgkin
×
tisagenlecleucel
×
Clear all
NCT03610724
2024-06-20
BIANCA
Novartis
Phase 2
Completed
34 enrolled
19 charts